The antigenic sites recognized by monoclonal antibodies with neutralizing activity for the Sabin vaccine strains of poliovirus of serotypes 1, 2 and 3 have been studied by the isolation and characterization of mutants resistant to neutralization by antibody. Three distinct sites have been identified which are designated site 1, site 2 and site 3. Site 1 includes a region of 12 amino acids of VP1, from residues 89 to 100, and a corresponding region of VP1 has been identified as an antigenic site for poliovirus 2. This site was strongly immunodominant in type 2 and type 3 but was not detected for poliovirus 1. Site 2 is a complex site including residues 220 to 222 from VP1 (site 2a) with residues including 169 and 170 and others of VP2 (site 2b). Both site 2a and site 2b have been detected in type 1 poliovirus, while as yet only site 2b has been detected in type 3 poliovirus. Site 3 is a complex site including residues 286 to 290 from VP1 (site 3a) with residues including 58 and 59 and others of VP3 (site 3b). Both sites 3a and 3b have been detected in type 3 poliovirus, while as yet only site 3b has been detected in type 1 poliovirus.
INTRODUCTION
Poliovirus is a picornavirus of the enterovirus genus occurring in three distinct serotypes. The virion consists of a single strand of messenger-sense RNA enclosed in a capsid made up of 60 copies of each of the four structural proteins VP1, VP2, VP3 and VP4. Nucleotide sequences of the genomic RNA of several strains of poliovirus have been published (Kitamura et al., 1981 ; Toyoda et al., 1984; Cann et al., 1984) and the X-ray crystallographic structure of the Mahoney strain of type 1 poliovirus has been solved to 2.9 A (0-29 nm) resolution .
Polioviruses are the causative agents of poliomyelitis, a disease which has been effectively controlled in the developed world by the use of vaccines, based on inactivated virus preparations (Salk & Salk, 1977) or on the live attenuated Sabin strains (Sabin & Boulger, 1973) . The disease remains a problem in those developing countries where vaccination programmes have not been introduced and there is evidence of a low level of poliomyelitis associated with the live vaccine strains, especially of type 3 (WHO report, 1981 ; Cann et al., 1984) . This has prompted studies of the antigenic structure of the virus, with a view to understanding the reasons for the efficacy of the existing vaccines, and to the development of new vaccines of improved safety and efficacy.
We have previously described studies on the antigenic structure of type 3 poliovirus Evans et al., 1983; Ferguson et al., 1985) which revealed the presence of a major immunodominant antigenic site in VP1 approximately one-third of the way from the N terminus. This principal site included residues 89 to 100 and a subsidiary site, also in VP1, was demonstrated which included residues 286 to 288. These studies were based on the isolation of antigenic variants using monoclonal antibodies, and the results were easily interpretable in the context of the X-ray crystallographic structure of type 1 poliovirus . Others have reported similar studies with type 1 poliovirus (Diamond et al., 1985; Blondel et al., 1986) .
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In this case, however, mutational loci were shown to occur in VP3 at residues 58 to 60 and 70 to 74 and in VP1 at residues 220 to 222 and in VP2 at 72 and 270. The differences in the positions of the mutational loci for type 1 and type 3 poliovirus were unexpected in view of the other general similarities between the viruses. We have therefore generated monoclonal antibodies and antigenic variants for all three serotypes. The data reported here confirm and extend the findings of others with regard to poliovirus type 1 and show that type 2 resembles type 3 in having a major immunodominant locus in VP1.
It has been reported that trypsin treatment of poliovirus specifically cleaves a region of the Sabin strain of poliovirus type 1 corresponding to the immunodominant site of type 3 (Fricks et al., 1985) . The Sabin strain of poliovirus type 3 is cleaved in a similar position (J. P. Icenogle et al., unpublished results) , effectively destroying the antigenicity of the immunodominant site. Virus which has been treated with trypsin is unable to react in immunoprecipitation tests with any of the monoclonal antibodies which select for mutations in the region of VP1 including residues 89 to 100, but does react normally with antibodies selecting for mutations in the subsidiary sites. We have therefore raised monoclonal antibodies to trypsin-treated type 3 virus, and demonstrate that they are directed to sites homologous to those found for type 1.
METHODS

Growth of virus and cells.
The Sabin strains of poliovirus of serotypes 1 (P1/LSc), 2 (P2/712Ch) and 3 (P3/Leonl2at b) were grown and assayed in Hep2c cells as described (Minor, 1980) . The Sabin strain of poliovirus type 3 was grown, purified and treated with trypsin as described (J. P. Icenogle et al., unpublished; Fricks et al., 1985) .
Preparation of monoclonal antibodies. Monoclonal antibodies were prepared by the fusion of splenocytes from immunized BALB/c mice with myeloma cells as described (Ferguson et al., 1984) . Hybridoma supernatants were screened using a modified single radial diffusion assay (antigen blocking test) and monoclonal antibodies were generally used as ascites prepared in syngeneic mice (Ferguson et al., 1984) . Immunization schedules and other protocols were similar in all fusions.
Selection of mutants. Antigenic variants were selected after plaque formation on Hep2c cells by virus treated with antibody under an agar overlay containing the antibody as described . Putative mutants were subjected to two cycles of selection, and small working pools grown from the secondary plaque plugs.
Antigenic" properties o[ mutants. The mutants were characterized for their reaction with other type-specific antibodies by the neutralization spot test described elsewhere in which 5 ~tl of a 1:100 dilution of virus pool was incubated with 20 rtl of a 1:10 dilution of ascitic fluid in a 96-well Linbro tray (Flow Laboratories). After 4 h incubation at room temperature, cells were added as 0.15 ml of a suspension containing 5 x 104 cells. Plates were stained with naphthalene black after 2 days incubation at 35 °C, when the cell sheet was either completely destroyed or completely preserved. In some instances the ability of the mutants to bind the antibodies was assessed in an antigen blocking test, using [3sS]methionine-labelled mutant virus.
Sequencing of mutants. Virus was grown in the presence of the antibody, purified and the genomic RNA was extracted before sequencing of particular regions by the dideoxy chain termination method using reverse transcriptase and synthetic primers as described elsewhere .
RESULTS
Antigenic sites in the neutralization of type 1 poliovirus
Mutants were selected with six antibodies with neutralizing activity for the Sabin strain of poliovirus type 1. The frequencies of isolation were between one in 10 *'° and one in 105"2 p.f.u, of parental virus, comparable to those previously reported for type 3 poliovirus and for type 1 poliovirus (Emini et al., 1982) . They are consistent with the frequencies expected for single point mutations in the genome of an RNA virus.
The antigenic patterns of reaction of mutants isolated with the six antibodies are shown in Table 1 . The panel included the six antibodies used for selection and five additional antibodies; the reactions of the mutants were measured in neutralization tests. Where the reactions have been examined in antigen blocking tests they paralleled the results shown in Table 1 . A total of 137 plaque isolates gave rise to nine distinct patterns of reaction (mutants 1 to 9) which could be divided into two separate non-overlapping groups including mutants 1 to 6 and 7 to 9 respectively. Mutants in groups 1 to 6 were resistant to some or all of monoclonal antibodies 423, 424, 1, 2, 3, 4, and 5, but not to antibodies 237, 271,646 and 431, while mutants 7 to 9 were resistant to some or all of antibodies 237, 271,646 and 431, but not to antibodies 423,424, 1, 2, 3, 4, and 5. This suggested that the two groups of antibodies were directed against different antigenic sites. Mutant 11 was selected from a mutant of group 6 with antibody 431, and was thus known to be a double mutant. The frequency at which mutant 11 arose was one in 104..4 p.f.u., while the frequency of isolation of mutants from the parental virus with antibody 431 was one in 105"2. These frequencies are not significantly different, and imply that the occurrence of a mutation giving the phenotype of mutant group 6 did not affect the reactions with antibody 431, or the frequency with which mutants resistant to antibody 431 could be selected. This also suggested that the two sites were distinct. Mutant 10 was the product of a single selection and was resistant to antibodies of both groups. However, this isolate arose at a frequency of one in 10 7"° and was selected with an antibody preparation obtained from a hybridoma which was subsequently recloned to give cell lines secreting antibodies of two distinct specificities. It is therefore most likely that the antibody preparation used to select mutant 10 contained two distinct antibodies, and that mutant 10 was a double mutant. Diamond et al. (l 985) reported the occurrence of mutations in the region of the genome coding for residues 60 and 70 from the N terminus of VP3 and in the region of the genome coding for residues 220 to 222 from the N terminus of VP1. Rossmann et al. (1985) have reported antigenically significant mutations in rhinovirus 14, another picornavirus, in a region of the genome coding for residues 158 to 162 from the N terminus of VP2. The homologous region has been reported to be antigenically significant in type 1 poliovirus using different criteria (Emini et al., 1984) . Mutants were therefore examined by primer extension sequencing through those regions of VP1, VP2 and VP3 described by others, as well as through the regions coding for residues 89 to 100 of VP 1 and 286 to 288 of VP 1 . The results are summarized in Table 2 . Mutants 1 to 6 had amino acid substitutions in VP3 at positions 58, 59, 60 or 71, while mutant 7 had a substitution in VP2 at position 170, and mutants 8 and 9 had substitutions in VP1 at residues 220 and 222 respectively. All mutants had the published sequence of the parental type 1 vaccine strain at all other loci examined (Toyoda et al., 1984) . Mutant 11 had substitutions in VP1 at position 220, and in VP3 at position 60, consistent with its origin as a product of two selections, and mutant 10 had substitutions in VP2 at position 169 and in VP3 at position 71, confirming that it too was a double mutant. It was notable that resistance to antibodies 237 and 271 could be conferred by suitable mutations in either VP2 or in VP1, and that antibodies 423, 424, 1, 2, 3, 4 and 5 which selected mutations in VP3 were extremely specific for the Sabin vaccine strain of type 1 poliovirus, failing to neutralize the related Mahoney strain. 
Antigenic sites in the neutralization of type 2 poliovirus
Attempts were made to select mutants from the Sabin strain of type 2 poliovirus (P2/P712Ch) using seven monoclonal antibodies. Mutants were successfully isolated at the expected frequencies with antibodies 269, 433,434 and 435. Antibodies 267 and 268 consistently failed to select any virus forming plaques. It was possible that antibodies 267 and 268 were the products of poorly cloned hybridomas, and thus polyclonal rather than monoclonal antibodies. Recloned preparations of the hybridomas also gave antibodies which did not give rise to mutants, however. Similarly, partially resistant variants could not be isolated from virus selected with antibody at concentrations near to the endpoint dilution. This might be expected to be possible where the preparation consisted of two antibodies of different titres. It also proved impossible to select variants resistant to 267 or 268 from mutants selected for resistance to all the other type 2-specific antibodies. It is therefore unlikely that 267 or 268 were mixtures of several antibodies, one of which was directed at the main mutational locus.
The patterns of reaction of the antigenic mutants isolated from type 2 poliovirus are shown in Table 3 . Five different reaction patterns were identified from 222 separate plaques picked, and the pattern indicated that antibodies 269, 433, 434, 435 and 436 were probably directed at a single antigenic site distinct from that recognized by either 267 or 268. The genomes of representative strains of each group of mutants were sequenced through a region including that coding for residues 89 to 100 of VP1, and single base substitutions were identified which led to the predicted amino acid substitutions given in Table 4 . Five separate substitutions at two amino acids resulted in the resistance pattern characteristic of group 1. The number of antibodies in the panel was small, and it is possible that a larger collection of antibodies would be able to distinguish between the different mutants of group 1. The mutations identified were clustered between residues 94 and 99 of VP1, in a region homologous to that of the principal . Antibodies 435 and 436 which recognized group 4 mutants also recognized mutations within this principal antigenic region. However, no substitution was found in group 4 mutants within codons 94 to 99 of VPI. When the sequence of the RNA was determined at other positions in VP1, however, a substitution leading to a lysine to glutamate change was detected at amino acid 174. This amino acid is close to the major neutralization site in the virus structure .
Antigenic sites in the neutralization of type 3 poliovirus
We have previously reported that 25 of 26 monoclonal antibodies with neutralizing activity for type 3 poliovirus were directed at a single region in VPI including amino acids 89 to 100. The 26th was directed at a region including amino acids 286 to 288 of VPI . The antibodies studied derived from both rats and mice, and from animals immunized with both vaccine and non-vaccine strains. Monoclonal antibodies deriving from immunizations with viruses having triple mutations within the principal site were still found to be directed against the site (M. Ferguson, unpublished) , implying that the sequence of the region from amino acids 89 to 100 in VP1 is not solely responsible for its immunodominance.
An antigenically drifted strain of type 3 poliovirus, P3/23 127/Finland/84, which was implicated in a recent outbreak of poliomyelitis in Finland was found to be resistant to neutralization by all monoclonal antibodies raised with the Sabin strain of type 3 poliovirus (Magrath et al., 1986) . Four out of five monoclonal antibodies prepared from animals immunized with P3/23127/Finland/84 were unable to react with the Sabin strain and may therefore have been directed against the region of the virus that was homologous to the immunodominant site of the Sabin strain of type 3 poliovirus. The remaining antibody, designated 792, neutralized P3/23127/Finland/84, the Sabin vaccine strain of type 3 poliovirus and all mutants with substitutions within the principal site. It was therefore probably directed against a different site.
Trypsin treatment destroys the immunodominant site on the Sabin vaccine strain of poliovirus type 3 (J. P. Icenogle et al., unpublished) . Monoclonal antibodies generated from animals immunized with trypsin-treated virus were able to neutralize both untreated virus and all mutants having substitutions within the principal antigenic site and were therefore probably directed at a different site. Mutants were selected with 792 and three of the antibodies generated with trypsin-treated virus. The frequencies of isolation were comparable to those previously reported .
The antigenic patterns of reaction of the mutants picked are shown in Table 5 , together with those of two mutants which have been previously described. Mutant 1 had an amino acid substitution in VP1 at position 98, where a glycine residue was found instead of an arginine and mutant 7 had a mutation in VP1 at position 287, where an aspartate residue was found in place of an asparagine. The 13 mutants fell into three distinct non-overlapping groups, implying the 
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existence of three independent antigenic sites. The genomic RNA of mutants 3 to 13 was sequenced by primer extension, through five regions corresponding to areas containing antigenically significant mutations in type 1 or type 3 poliovirus. These included regions coding for residues 89 to 100, 220 to 222 and 286 to 290 of VP1, residues 50 to 80 of VP3 and residues t 60 to 180 of VP2. The results are presented in Table 6 . Mutants of groups 2 to 6 had mutations within VP2 at residues 164, 166, 167 and 171. Two distinct mutants of group 6 were found, with either a threonine or a lysine substituted for the asparagine in VP2 at residue 164. Mutants 7 to 13 had single base substitutions resulting in predicted amino acid changes in VP1 at residues 287 and 290, and in VP3 at residues 58, 59, 77 and 79. It was notable that the reactions of antibodies 1023, 840, 251, 557, 1084 and 1007 were affected both by mutations within VP3 at residues 58 and 59 and by mutations within VP1 at residues 287 and 290. No mutation was found other than those listed in Table 6 for any of the mutants. DISCUSSION We have previously reported the existence of a major antigenic locus in type 3 poliovirus which includes residues 89 to 100 VP1, and a subsidiary locus including residues 286 to 288 . These findings contrast with the results reported for type 1 poliovirus by others (Diamond et al., 1985; Blondel et al., 1986) which describe antigenically significant mutational loci in VP3 between residues 58 and 71, in VP1 between residues 220 and 222 and in VP2 at residues 72 and 270. The data reported here confirm and extend these results for type 1, demonstrating that monoclonal antibodies produced by the protocol previously used to generate antibodies specific for type 3, select for mutations outside the region of VP1 which is an immunodominant antigenic locus in type 3 poliovirus Evans et al., 1983; Ferguson et al., 1985) . We suggest that the difference between the serotypes is thus not an artefact of the methods used to obtain either the monoclonal antibodies or the antigenic variants, but represents a real difference between type 1 and type 3 polioviruses. However, when animals were immunized with an antigenically unusual type 3 poliovirus, or a trypsinized preparation of Sabin type 3 virus in which the major site was destroyed, it was possible to obtain monoclonal antibodies which recognized antigenic sites homologous to those of type 1 poliovirus. This suggests that although site 1 of type 3 poliovirus may be immunodominant, other subsidiary sites exist and may induce neutralizing antibodies once the immunodominant site is removed. An antibody has been described which will recognize residues 93 to 100 of VP1 of type 1 poliovirus and has neutralizing activity van der Werfet al., 1983) . This is the only known antibody directed against the region homologous to the principal site of type 3 poliovirus. The reason why this site for type 1 poliovirus is ineffective in eliciting an antibody response is not known.
The Sabin strain of poliovirus type 2 resembles poliovirus type 3 in so far as most of the antibodies examined selected for mutations within the region homologous to the principal site of poliovirus type 3. Studies using trypsin-treated Sabin type 2 virus are in progress to obtain antibodies against other sites. However, mutants could not be isolated with two antibodies and it is possible that this is because such mutants were non-viable. The site recognized by these antibodies is therefore of considerable interest.
All mutants which have been selected with monoclonal antibodies, including those reported here and previously , have been mapped onto the X-ray crystallographic structure of poliovirus type 1 . Mutations considered to be within a single antigenic site on the basis of their effect on the reactions of the virus with antibodies have been shown to be clustered together in a distinct area, and operationally distinct antigenic sites have been shown to be physically separate. The similarities between type 1 poliovirus and trypsintreated type 3 poliovirus are also striking. It is therefore unlikely that the mutations are having effects on the conformation of distant antigenic sites (Diamond et al., 1985; Blondel et al., 1986) . For influenza virus (Knossow et al., 1984) a mutation conferring resistance to an antibody has been shown to affect only the local structure and therefore not to induce distant effects on conformation. This is of particular relevance to the site of poliovirus type 1 composed of elements of VP2 including residues 169 and 170 and elements of VP 1 including residues 220 and 222. These two regions are close together on the virion surface , and form a single operationally defined site. Similarly, the site on poliovirus type 3 composed of elements of VP3 including residues 58, 59, 77 and 79 and elements of VP1 including residues 286 to 290 are close on the virion surface of type 1 poliovirus and therefore probably also of type 3. This site is the target of the strain-specific monoclonal antibody 138 . Strain-specific antibodies have been shown to select mutations within the homologous site of VP3 of type 1 poliovirus (Diamond et al., 1985 ; Blondel et al., 1986) and are therefore probably directed against the equivalent region. Antigenic differences between infectious virions and empty capsids have been well documented (Le Bouvier, 1959) and interpreted in terms of conformational differences. The existence of composite sites consisting of residues from two proteins is consistent with these observations in that major antigenic changes might result from changes in the arrangements of the virion proteins. The sites identified here are summarized in Table 7 for the three serotypes of poliovirus. The region including residues 89 to 100 of VP1 is designated site 1, the region including residues 220 to 222 of VP 1 is designated site 2a as it forms part of a composite site with residues 164 to 172 of VP2, designated site 2b. Similarly, site 3a includes residues 286 to 290 of VP1, and site 3b includes residues 58 to 60, 70, 7l, 77 and 79 of VP3. Site 3a was formerly referred to as site 2 . Other workers have studied the antigenic structure of rhinovirus 14, by methods similar to those described here Rossmann et al., 1985) and the similarities in the antigenic structures of poliovirus and rhinovirus 14 are very striking. In particular, a region homologous to the principal VP1 site of type 2 and type 3 has been identified (Nimla), a region homologous to the composite VP2 and VP1 site has been shown to include elements of both VP2 and VP1 (NimlI), and a site has been located in VP3 and the C terminus of VP1 (NimlII).
The degree to which the various antigenic sites of poliovirus described here contribute to immunity to disease is the subject of current investigations.
